Selected Papers from the 1st International Electronic Conference on Vaccines: RNA Vaccines, Current Challenges and Future Developments (IECV2023)

Dear Colleagues,

This Special Issue comprises selected papers from the 1st International Electronic Conference on Vaccines: RNA Vaccines, Current Challenges and Future Developments (IECV2023), hosted online from 1 to 15 December 2023, an online platform for hosting scholarly e-conferences and discussion groups (https://iecv2023.sciforum.net/). 

IECV2023 will present the latest studies in process/system-related research in vaccine and RNA technology fields. The goal is to show the current state, challenges, opportunities and future trends in RNA vaccines. 

• Vaccines to counter anti-microbial resistance;
• Vaccines to eradicate endemic disease-opportunities and challenges;
• Vaccines to prevent zoonotic transmission-targeting the animal reservoir;
• Vaccine platforms—advantages and disadvantages;
• Clinical trial design for reactive and preventive vaccination;
• Vaccine deployment in outbreak settings—lessons learned;
• Advances in vaccine formulation and adjuvantisation;
• Clinical view on routinisation of RNA vaccines;
• How do we prepare for vaccines against the as yet unknown?;
• COVID-19 vaccine hesitancy;
• Immune response after vaccination against SARS-CoV-2 in patients with chronic diseases;
• T-cell responses in SARS-CoV-2;
• SARS-CoV-2 variant and vaccine development;
• Novel technology and vaccines development for COVID-19;
• T-cell immunity and HIV-1 pathogenicity;
• Neurological complications following COVID-19 infection and COVID-19 vaccination;
• Vaccine hesitancy;
• Vaccine safety;
• Vaccine ingredients;
• Vaccine schedule;
• Vaccine objections;
• Vaccines influence on education;
• Cost-effectiveness of vaccines;
• Vaccine transportation;
• Methods of vaccination;
• Vaccine-related policy.

Dr. François Meurens
Dr. Fanny Renois
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• immunological mechanisms
• viral immunology
• immunopathogenesis
• vaccine development and efficacy evaluation, immune responses to vaccines
• vaccine technology
• vaccine vectors adjuvants and Iimunomodulators
• immunomodulation
• prophylactic Vaccines